Erasca Reports Second Quarter 2025 Business Updates and Financial Results
Provided By GlobeNewswire
Last update: Aug 12, 2025
Efficient execution accelerated clinical entry of pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001
Phase 1 monotherapy data for RAS-targeting franchise expected in 2026
Read more at globenewswire.com
